DE69633664D1 - Genetische marker für brust und eierstockkrebs - Google Patents

Genetische marker für brust und eierstockkrebs

Info

Publication number
DE69633664D1
DE69633664D1 DE69633664T DE69633664T DE69633664D1 DE 69633664 D1 DE69633664 D1 DE 69633664D1 DE 69633664 T DE69633664 T DE 69633664T DE 69633664 T DE69633664 T DE 69633664T DE 69633664 D1 DE69633664 D1 DE 69633664D1
Authority
DE
Germany
Prior art keywords
specific
mutations
brca1
antibodies
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633664T
Other languages
English (en)
Other versions
DE69633664T2 (de
Inventor
Mary-Claire King
Lori Friedman
Beth Ostermeyer
Sarah Rowel
Eric Lynch
Csilla Szabo
Ming Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69633664D1 publication Critical patent/DE69633664D1/de
Publication of DE69633664T2 publication Critical patent/DE69633664T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69633664T 1995-04-19 1996-04-19 Genetische marker für brust und eierstockkrebs Expired - Lifetime DE69633664T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US425061 1995-04-19
US08/425,061 US5622829A (en) 1993-12-08 1995-04-19 Genetic markers for breast, ovarian, and prostatic cancer
PCT/US1996/005621 WO1996033271A2 (en) 1995-04-19 1996-04-19 Genetic markers for breast and ovarian cancer

Publications (2)

Publication Number Publication Date
DE69633664D1 true DE69633664D1 (de) 2004-11-25
DE69633664T2 DE69633664T2 (de) 2006-02-23

Family

ID=23684980

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633664T Expired - Lifetime DE69633664T2 (de) 1995-04-19 1996-04-19 Genetische marker für brust und eierstockkrebs

Country Status (9)

Country Link
US (3) US5622829A (de)
EP (1) EP0821733B1 (de)
JP (1) JPH11503915A (de)
AT (1) ATE280226T1 (de)
AU (1) AU698800B2 (de)
CA (1) CA2217668C (de)
DE (1) DE69633664T2 (de)
ES (1) ES2231808T3 (de)
WO (1) WO1996033271A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014051A1 (en) * 2002-07-18 2004-01-22 Isis Pharmaceuticals Inc. Antisense modulation of breast cancer-1 expression
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
US6210941B1 (en) 1997-06-27 2001-04-03 The Trustees Of Boston University Methods for the detection and isolation of proteins
US5643722A (en) 1994-05-11 1997-07-01 Trustees Of Boston University Methods for the detection and isolation of proteins
US6403303B1 (en) * 1996-05-14 2002-06-11 Visible Genetics Inc. Method and reagents for testing for mutations in the BRCA1 gene
US6428955B1 (en) 1995-03-17 2002-08-06 Sequenom, Inc. DNA diagnostics based on mass spectrometry
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
US6083698A (en) * 1995-09-25 2000-07-04 Oncormed, Inc. Cancer susceptibility mutations of BRCA1
DE19629938C1 (de) * 1996-07-24 1997-11-27 Gsf Forschungszentrum Umwelt E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren
US5905026A (en) 1996-08-27 1999-05-18 Cornell Research Foundation, Inc. Method of detecting expression of and isolating the protein encoded by the BRCA1 gene
WO1998012327A2 (en) * 1996-09-20 1998-03-26 Board Of Regents, The University Of Texas System Compositions and methods comprising bard1 and other brca1 binding proteins
AU5093898A (en) * 1996-10-31 1998-05-22 Jennifer Lescallett Primers for amplification of brca1
WO1998020166A2 (en) * 1996-11-06 1998-05-14 Sequenom, Inc. Dna diagnostics based on mass spectrometry
US5965377A (en) * 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
EP0878552A1 (de) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
EP0983389A1 (de) * 1997-06-04 2000-03-08 Rijksuniversiteit te Leiden Testsatz und verfahren für den nachweis von einer rädisposition zum ovarial und brustkrebs
US7014993B1 (en) * 1997-08-21 2006-03-21 The Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6030832A (en) * 1997-11-21 2000-02-29 Myriad Genetics, Inc. Carboxy-terminal BRCA1 interacting protein
EP1078098A1 (de) * 1998-05-04 2001-02-28 Dako A/S Verfahren und sonden zur detektion chromosomaler aberrationen
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
DK1520588T3 (en) 1998-07-13 2015-03-23 Univ Texas Use of antibodies to aminophospholipids for cancer treatment
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
AU5128799A (en) * 1998-07-24 2000-02-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pb 39, a gene dysregulated in prostate cancer, and uses thereof
EP1234585A3 (de) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Zusammensetzungen zur Vorbeugung oder Behandlung von Krebs
WO2000075161A2 (en) 1999-06-04 2000-12-14 Massachusetts Institute Of Technology Compositions and methods for the screening of compounds to enhance or reduce apoptosis
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
US20030064372A1 (en) * 2000-06-22 2003-04-03 Bodnar Jackie S. Gene and sequence variation associated with lipid disorder
US6703204B1 (en) 2000-07-28 2004-03-09 The Brigham & Women's Hospital, Inc. Prognostic classification of breast cancer through determination of nucleic acid sequence expression
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
US7465540B2 (en) * 2000-09-21 2008-12-16 Luminex Corporation Multiple reporter read-out for bioassays
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
WO2002099418A1 (en) * 2001-06-04 2002-12-12 Research Development Foundation Premalignant, serially-transplantable breast tissue lines and uses thereof
AU2003253629A1 (en) * 2002-06-07 2003-12-22 Myriad Genetics, Inc Large deletions in human brca1 gene and use thereof
MX337052B (es) 2002-07-15 2016-02-11 Univ Texas Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer.
US8431396B2 (en) 2003-03-21 2013-04-30 The Cleveland Clinic Foundation Anti-angiogenic peptides
MXPA06008293A (es) 2004-01-22 2007-06-11 Univ Miami Formulaciones topicas de coenzima q10 y metodos de uso.
BRPI0820298A8 (pt) 2007-11-09 2018-05-08 Affitech Res As composições e métodos de anticorpos anti-vegf
US8167949B2 (en) * 2008-01-25 2012-05-01 Aesculap Implant Systems, Llc Hydrostatic interbody
CN111253483B (zh) * 2020-03-02 2021-07-30 江苏莱森生物科技研究院有限公司 一种抗brca1单克隆抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742000A (en) * 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
ES2164045T3 (es) * 1990-06-27 2002-02-16 Univ Princeton Sondas para la deteccion de p53 mutante.
US5597707A (en) * 1993-04-15 1997-01-28 Bristol-Myers Squibb Company Tumor associated antigen recognized by the murine monoclonal antibody L6, its oligonucleotide sequence and methods for their use
US5622829A (en) * 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer

Also Published As

Publication number Publication date
AU698800B2 (en) 1998-11-05
WO1996033271A2 (en) 1996-10-24
AU5566896A (en) 1996-11-07
EP0821733B1 (de) 2004-10-20
JPH11503915A (ja) 1999-04-06
ES2231808T3 (es) 2005-05-16
ATE280226T1 (de) 2004-11-15
EP0821733A2 (de) 1998-02-04
DE69633664T2 (de) 2006-02-23
WO1996033271A3 (en) 1997-03-20
US5622829A (en) 1997-04-22
CA2217668A1 (en) 1996-10-24
US6512091B1 (en) 2003-01-28
US5821328A (en) 1998-10-13
CA2217668C (en) 1999-11-16

Similar Documents

Publication Publication Date Title
DE69633664D1 (de) Genetische marker für brust und eierstockkrebs
Raza-Egilmez et al. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia
Mollenhauer et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25. 3–26.1 is deleted in malignant brain tumours
CA3057330A1 (en) Treating cancer with cas endonuclease complexes
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
DE69834190D1 (de) 5' ests für sekretierte proteine die im gehirn expremiert werden
DE69835751D1 (de) 5' ests für proteine, die nicht gewebespezifisch sind
Crossen et al. Identification of amplified genes in a patient with acute myeloid leukemia and double minute chromosomes
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
Ulvsbäck et al. Gene structure of semenogelin I and II. The predominant proteins in human semen are encoded by two homologous genes on chromosome 20.
DE69834727D1 (de) 5' ests für sekretierte proteine die in verschiedenen geweben expremiert werden
MXPA02008239A (es) Gen humano de la esquizofrenia.
WO2001014420A3 (en) Novel members of the plexin family and uses thereof
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE245190T1 (de) Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
JPH05502789A (ja) ムチンヌクレオチド
WO2003105773A3 (en) MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
PT771352E (pt) Genes e operoes estruturais lkp pilina de haemophilus influenzae nao caracteristica
US20200206322A1 (en) Treating cancer with cas endonuclease complexes
Bala et al. Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene
ES2189560B1 (es) Dna polimerasa k, nuevo marcador tumoral.
US8580929B2 (en) DNA sequence encoding a retinoic acid regulated protein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition